AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12711184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the distal small bowel
Number of subjects: 9
Study 12711184 — intervention group
Group type: EXPERIMENTAL
Intervention: Oseltamivir administered via Enterion capsule (150 mg) to the ascending colon
Number of subjects: 9
Study 9857539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound examination of preepiglottic space
Number of subjects: 73
Study 9857539 — intervention group
Group type: COMPARATOR
Intervention: CT examination of preepiglottic space
Number of subjects: 73
Study 7835241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) for insulinoma
Number of subjects: 13
Study 7835241 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (SRS) for insulinoma
Number of subjects: 13
Study 7835241 — intervention group
Group type: COMPARATOR
Intervention: CT, US, and MRI together for insulinoma
Number of subjects: 13
Study 7835241 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography (EUS) for gastrinoma
Number of subjects: 13
Study 7835241 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatostatin receptor scintigraphy (SRS) for gastrinoma
Number of subjects: 13
Study 7835241 — intervention group
Group type: COMPARATOR
Intervention: CT, US, and MRI together for gastrinoma
Number of subjects: 13
Study 1977432 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine 4 micrograms kg‐1 min‐1
Number of subjects: 20
Study 1977432 — intervention group
Group type: COMPARATOR
Intervention: Dopamine 5 micrograms kg‐1 min‐1
Number of subjects: 20
Study 307546 — intervention group
Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan plus carbidopa
Number of subjects: 3
Study 307546 — intervention group
Group type: COMPARATOR
Intervention: Placebo I
Number of subjects: 3
Study 307546 — intervention group
Group type: COMPARATOR
Intervention: Placebo II
Number of subjects: 3
Study 307546 — intervention group
Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 3
Study 31589276 — intervention group
Group type: EXPERIMENTAL
Intervention: Free distribution of essential medicines (n = 395)
Number of subjects: 786
Study 31589276 — intervention group
Group type: COMPARATOR
Intervention: Usual access to medicines (n = 391)
Number of subjects: 786
Study 31589276 — intervention group
Group type: EXPERIMENTAL
Intervention: Free distribution of essential medicines
Number of subjects: 786
Study 28432326 — intervention group
Group type: EXPERIMENTAL
Intervention: T stem cell memory (TSCM) cells identified by phenotypic markers of CD4+ T cells; subsets characterized by IL-2/IL-15 receptors and APOBEC3G anti-viral restriction factors; no specific dosage or duration mentioned.
Number of subjects: 0
Study 28432326 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous HSP70 activation of TSCM and innate immunity pathways; no specific dosage or duration mentioned.
Number of subjects: 0
Study 25464418 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 1498
Study 25464418 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1498
Study 23549382 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide (n = 31)
Number of subjects: 91
Study 23549382 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia with 30% oxygen (n = 30)
Number of subjects: 91
Study 23549382 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide-free anesthesia with 80% oxygen (n = 30)
Number of subjects: 91
Study 21323294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty (THA) after thorough debridement
Number of subjects: 8
Study 21323294 — intervention group
Group type: EXPERIMENTAL
Intervention: Cementless total hip arthroplasty (THA)
Number of subjects: 8
Study 19804459 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking characters in a movie segment
Number of subjects: 65
Study 19804459 — intervention group
Group type: COMPARATOR
Intervention: Non-smoking characters in a movie segment
Number of subjects: 65
Study 16706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond
Number of subjects: 70
Study 16706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond Solo Plus Self‐Etch
Number of subjects: 70
Study 16706298 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond and Optibond Solo Plus Self‐Etch
Number of subjects: 70
Study 15656396 — intervention group
Group type: EXPERIMENTAL
Intervention: Emoxipine
Number of subjects: 0
Study 15656396 — intervention group
Group type: EXPERIMENTAL
Intervention: Reamberine
Number of subjects: 0
Study 15656396 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexidole
Number of subjects: 0
Study 15656396 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11728760 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (AC) mixed with regular cola
Number of subjects: 15
Study 11728760 — intervention group
Group type: COMPARATOR
Intervention: Activated charcoal (AC) mixed with diet cola
Number of subjects: 15
Study 9226208 — intervention group
Group type: EXPERIMENTAL
Intervention: Liothyronine (L-T3)
Number of subjects: 17
Study 8429321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin treatment (IVIg) for 5 consecutive days
Number of subjects: 28
Study 8429321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 8429321 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intravenous immunoglobulin treatment (IVIg)
Number of subjects: 28
Study 8429321 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological studies
Number of subjects: 28
Study 3618665 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal ambulation
Number of subjects: 100
Study 3618665 — intervention group
Group type: COMPARATOR
Intervention: Bed rest
Number of subjects: 100
Study 31808538 — intervention group
Group type: EXPERIMENTAL
Intervention: Serratus plane block
Number of subjects: 94
Study 31808538 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesics (control group)
Number of subjects: 94
Study 31203245 — intervention group
Group type: EXPERIMENTAL
Intervention: Salt-reduction behaviours (SRB score) intervention
Number of subjects: 603
Study 31203245 — intervention group
Group type: COMPARATOR
Intervention: Social support from family members
Number of subjects: 603
Study 31203245 — intervention group
Group type: COMPARATOR
Intervention: Class size and friendship connections
Number of subjects: 603
Study 31203245 — intervention group
Group type: COMPARATOR
Intervention: Teacher intervention programme attendance
Number of subjects: 603
Study 27393218 — intervention group
Group type: EXPERIMENTAL
Intervention: Caphosol mouthwash plus standard oral care
Number of subjects: 215
Study 27393218 — intervention group
Group type: COMPARATOR
Intervention: Standard oral care alone
Number of subjects: 215
Study 25591439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialysate APR (2.5% glucose-based peritoneal dialysis solution)
Number of subjects: 96
Study 25591439 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer solution APR
Number of subjects: 96
Study 25591439 — intervention group
Group type: COMPARATOR
Intervention: Shock group (conventional intravenous resuscitation)
Number of subjects: 96
Study 23151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-1000 (1000 mg/d of quercetin, 250 mg/d of vitamin C and 10 mg/d of niacin)
Number of subjects: 100
Study 23151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Q-500 (500 mg/d of quercetin, 125 mg/d of vitamin C and 5 mg/d of niacin)
Number of subjects: 100
Study 23151341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 22183994 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal triamcinolone acetate
Number of subjects: 14
Study 22183994 — intervention group
Group type: COMPARATOR
Intervention: Laser treatment
Number of subjects: 14
Study 19328244 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced nurse case management (NCM)
Number of subjects: 549
Study 18180897 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded therapy featuring integrative traditional Chinese and Western medicine including 1.8 g of Xuefuda orally once per day, intravenous dripping of 250 mL of hemostasis mixture twice a day, 1.2 g of clindamycin per day for stage I; Kangyanling intra-articular injection for stage II-III; 25 mg of sodium hyaluronate for stage IV.
Number of subjects: 40
Study 15016940 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest clinic follow up (intervention group)
Number of subjects: 25
Study 15016940 — intervention group
Group type: COMPARATOR
Intervention: Regular primary care (control group)
Number of subjects: 25
Study 11171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypermethylation of the CDH1 promoter region in UCACRC
Number of subjects: 28
Study 11171827 — intervention group
Group type: COMPARATOR
Intervention: Hypermethylation of the CDH1 promoter region in SCRC
Number of subjects: 28
Study 11171827 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of hypermethylation with E-cadherin expression
Number of subjects: 28
Study 9869552 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood volume determination and plasma catecholamines measurement during episodes
Number of subjects: 21
Study 9138872 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Pomeroy tubal ligation
Number of subjects: 57
Study 9138872 — intervention group
Group type: COMPARATOR
Intervention: Standard coagulation
Number of subjects: 57
Study 2574594 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg twice daily
Number of subjects: 28
Study 2574594 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 1062298 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate
Number of subjects: 15
Study 1062298 — intervention group
Group type: COMPARATOR
Intervention: H2O2
Number of subjects: 15
Study 30962268 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (Escherichia coli lipopolysaccharide, LPS, 0.8 ng/kg body weight)
Number of subjects: 20
Study 30962268 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 20
Study 27770397 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation therapy (ADT) for 6 months
Number of subjects: 77
Study 27770397 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation therapy (ADT) for 36 months
Number of subjects: 77
Study 27770397 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessments using QLQ-C30 and QLQ PR-25
Number of subjects: 77
Study 25542824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone intervention (CPI)
Number of subjects: 350
Study 25542824 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 350
Study 23701149 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mcg vaginal misoprostol
Number of subjects: 60
Study 23701149 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mcg vaginal misoprostol
Number of subjects: 60
Study 23701149 — intervention group
Group type: COMPARATOR
Intervention: Control group (no misoprostol)
Number of subjects: 60
Study 21569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic fitness (20 m shuttle run)
Number of subjects: 245
Study 21569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Agility test (obstacle course)
Number of subjects: 245
Study 21569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline aerobic fitness
Number of subjects: 245
Study 21569343 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline dynamic balance (balance beam)
Number of subjects: 245
Study 18094221 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg rifampin
Number of subjects: 10
Study 18094221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 16921044 — intervention group
Group type: EXPERIMENTAL
Intervention: No systemic therapy
Number of subjects: 313
Study 16921044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 313
Study 16921044 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen alone
Number of subjects: 313
Study 16921044 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus tamoxifen
Number of subjects: 313
Study 16921044 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all groups)
Number of subjects: 313
Study 12547376 — intervention group
Group type: EXPERIMENTAL
Intervention: Applied Tension (AT)
Number of subjects: 44
Study 12547376 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no AT)
Number of subjects: 44
Study 11016021 — intervention group
Group type: EXPERIMENTAL
Intervention: Lysine acetylsalicylate (LA) 320 mg
Number of subjects: 10
Study 11016021 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 320 mg
Number of subjects: 10
Study 9367285 — intervention group
Group type: EXPERIMENTAL
Intervention: CEx (Cycle Ergometer Exercise at 23 degrees C)
Number of subjects: 11
Study 9367285 — intervention group
Group type: COMPARATOR
Intervention: CS (Seated Control at 23 degrees C)
Number of subjects: 11
Study 9367285 — intervention group
Group type: EXPERIMENTAL
Intervention: HEx (Heat Exercise at 40 degrees C)
Number of subjects: 11
Study 9367285 — intervention group
Group type: COMPARATOR
Intervention: HS (Heat Seated Control at 40 degrees C)
Number of subjects: 11
Study 8263981 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured allograft dressings (CCAD)
Number of subjects: 5
Study 8263981 — intervention group
Group type: COMPARATOR
Intervention: Tulle‐gras dressings
Number of subjects: 5
Study 2939219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (K), 40 mg twice daily
Number of subjects: 32
Study 2939219 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (M), 100 mg twice daily
Number of subjects: 32
Study 2939219 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (K)
Number of subjects: 32
Study 2939219 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (M)
Number of subjects: 32
Study 30027406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexanic extract of Serenoa repens (HESr) 320 mg/day
Number of subjects: 97
Study 30027406 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 97
Study 29971969 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-frequency electrical muscle stimulation (LF‐EMS)
Number of subjects: 35
Study 29971969 — intervention group
Group type: COMPARATOR
Intervention: Sham (skin level stimulation only)
Number of subjects: 35
Study 26883089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde
Number of subjects: 0
Study 26883089 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 0
Study 26883089 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnamaldehyde and Capsaicin
Number of subjects: 0
Study 26883089 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24939648 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous oxygen supplementation for 72 hours
Number of subjects: 8000
Study 24939648 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen supplementation for three nights
Number of subjects: 8000
Study 24939648 — intervention group
Group type: COMPARATOR
Intervention: No routine oxygen supplementation
Number of subjects: 8000
Study 23001689 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention promoting breastfeeding, reducing sugar-sweetened beverage consumption, appropriate timing of healthy solid foods introduction, and counseling to reduce sedentary lifestyles
Number of subjects: 577
Study 23001689 — intervention group
Group type: COMPARATOR
Intervention: Comparison condition (control group)
Number of subjects: 577
Study 20684401 — intervention group
Group type: EXPERIMENTAL
Intervention: Various strategies to avoid physician's inertia and combat patient's non-compliance, including titration, rescue medications, and self-monitoring.
Number of subjects: 0
Study 20684401 — intervention group
Group type: EXPERIMENTAL
Intervention: Pill count for compliance verification during the placebo run-in period.
Number of subjects: 0
Study 20684401 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical analysis restricted to individuals adhering to the study protocol (per protocol analysis).
Number of subjects: 0
Study 17432675 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture group with 'Jin's three‐needling'
Number of subjects: 58
Study 17432675 — intervention group
Group type: COMPARATOR
Intervention: Medication group treated with anti‐anxiety drugs
Number of subjects: 58
Study 17432675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 15523456 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact diode laser (CDL) tonsillectomy
Number of subjects: 58
Study 15523456 — intervention group
Group type: COMPARATOR
Intervention: Monopolar cautery (MPC) tonsillectomy
Number of subjects: 58
Study 11305823 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopexamine infusion (0.5 - 2 microg x kg(‐1) x min(‐1))
Number of subjects: 24
Study 11305823 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo infusion)
Number of subjects: 24
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrethroid (permethrin and lambdacyhalothrin) impregnated bednets with community education programme
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based impregnation programme
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational methods and promotion of dark-colour nets
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Impregnation of bednets
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretesting of soaking capacity of different net materials
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructions for impregnation procedures
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of very cheap thin net materials
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Monitoring of side-effects of last-generation pyrethroids
Number of subjects: 0
Study 9236827 — intervention group
Group type: EXPERIMENTAL
Intervention: Further studies on protective efficacy of bednets
Number of subjects: 0
Study 7937768 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial glucose step at 3.61 mmol/liter
Number of subjects: 12
Study 7937768 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial glucose step at 4.16 mmol/liter
Number of subjects: 12
Study 7937768 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial glucose step at 3.05 mmol/liter
Number of subjects: 12
Study 7937768 — intervention group
Group type: EXPERIMENTAL
Intervention: Final day glucose clamp starting at 4.16 mmol/liter
Number of subjects: 12
Study 7937768 — intervention group
Group type: EXPERIMENTAL
Intervention: Final day glucose concentration of 2.50 mmol/liter
Number of subjects: 12
Study 7937768 — intervention group
Group type: EXPERIMENTAL
Intervention: Final day glucose steps
Number of subjects: 12
Study 2894232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg twice daily
Number of subjects: 2435
Study 2894232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 300 mg once daily
Number of subjects: 2435
Study 2894232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2435
Study 2894232 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (both doses)
Number of subjects: 2435
Study 30484837 — intervention group
Group type: EXPERIMENTAL
Intervention: sacubitril-valsartan
Number of subjects: 8399
Study 30484837 — intervention group
Group type: COMPARATOR
Intervention: ACEI
Number of subjects: 8399
Study 30484837 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 8399
Study 30484837 — intervention group
Group type: COMPARATOR
Intervention: β-blockers
Number of subjects: 8399
Study 30484837 — intervention group
Group type: COMPARATOR
Intervention: Mineralocorticoid antagonists
Number of subjects: 8399
Study 30484837 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator
Number of subjects: 8399
Study 30484837 — intervention group
Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy
Number of subjects: 8399
Study 28147451 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Alexander lessons over 12 weeks and usual care
Number of subjects: 120
Study 28147451 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 120
Study 26200278 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 25 mg/m every 21 days
Number of subjects: 0
Study 26200278 — intervention group
Group type: COMPARATOR
Intervention: Topotecan 1.5 mg/m on days 1-5 every 21 days
Number of subjects: 0
Study 22610788 — intervention group
Group type: EXPERIMENTAL
Intervention: sGC-RT (sequential CRT with gemcitabine and cisplatin)
Number of subjects: 240
Study 22610788 — intervention group
Group type: COMPARATOR
Intervention: Con-RT (cisplatin-based concurrent chemoradiotherapy plus adjuvant PF chemotherapy)
Number of subjects: 240
Study 21143244 — intervention group
Group type: EXPERIMENTAL
Intervention: Trier Social Stress Test
Number of subjects: 79
Study 21143244 — intervention group
Group type: COMPARATOR
Intervention: No-stress control condition
Number of subjects: 79
Study 21143244 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Trier Social Stress Test and No-stress control)
Number of subjects: 79
Study 18212696 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (0.5 microg/kg/min infusion)
Number of subjects: 77
Study 18212696 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenaline (0.01-0.02 microg/kg/min)
Number of subjects: 77
Study 18212696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no inotropes)
Number of subjects: 77
Study 17021320 — intervention group
Group type: EXPERIMENTAL
Intervention: AIC vaccine
Number of subjects: 25
Study 12554027 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate- or high-intensity counseling interventions including interactive health communication tools
Number of subjects: 21
Study 12554027 — intervention group
Group type: COMPARATOR
Intervention: Brief counseling by primary care providers
Number of subjects: 21
Study 12554027 — intervention group
Group type: EXPERIMENTAL
Intervention: More-intensive interventions
Number of subjects: 21